Integration of PAT in Biopharmaceutical Research: A Case Study - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Integration of PAT in Biopharmaceutical Research: A Case Study
This case study describes the implementation of process analytical technology on the cultivation process step of a whole-cell vaccine against whooping cough disease.


Pharmaceutical Technology
Volume 33, Issue 7

Evaluating product quality


Figure 1: Batch profile analysis for the cultivation of Bordetella pertussis. Diagram (a) shows the increase in cell numbers for four cultivations and the decrease in average concentrations of the nutrients lactate and glutamate. Lines A to K in Diagram A indicate the points at which samples for microarray analysis were taken. Diagram (b) shows the relative product quality scores at the sample points A to K based on Diagram (a). It is clearly shown that the product quality score is consistently high for most of the process. Toward the end of the cultivation (as shown by points J and K), the product quality drops sharply. This decline corresponds with the depletion of important nutrients (Diagram a) in real time.
The product quality score was used to determine a critical event in batch cultivation: the optimal harvest point (9). As biomass accumulates exponentially, nutrient concentrations drop exponentially (see Figure 1), which can result in a range of unwanted effects, including cell lysis or the suppression of virulence genes (10). To investigate the optimal harvest point, four identically operated cultivations were each sampled at 11 time points for microarray analysis. A continuously changing gene expression pattern was expected because of the continuously changing extracellular environment associated with batch cultivation. However, gene expression proved to be relatively constant, which resulted in high product quality scores during most of the cultivation. Toward the end of cultivation, the product quality score dropped sharply (see Figure 1). This drop coincided with the depletion of the nutrients lactate and glutamate, a determination that allowed the optimal harvest point to be accurately predicted. Therefore, measuring lactate and glutamate concentrations during cultivation demonstrated that the bacteria can be consistently harvested before nutrients become limiting, assuring the optimal composition of the bacterial outer membrane.

Critical process parameters

The definition of PAT states that it is a "system for designing, analyzing and controlling manufacturing through timely measurements of critical quality and performance attributes of raw and in-process materials and processes, with the goal of ensuring final product quality" (1). With the on-line measurement of nutrient concentrations and the supporting evidence that this correlates with virulence gene expression and subsequently outer membrane composition, the requirements for a PAT application are fulfilled, at least for the harvest-point determination. For other critical process attributes, several sensors are available to measure pH or dissolved oxygen, for example. However, these sensors only monitor a single parameter, which means one could risk missing a critical parameter or be required to mount numerous probes on the bioreactor system for each measured parameter. To monitor many parameters simultaneously, a near infrared (NIR) spectroscopic probe that measured a spectrum between 800 and 2500 nm was placed inside the bioreactor. The instrument's range, situated between visible light and far infrared, is sensitive for chemical changes (band vibration overtones) and physical changes (combination bands) such as optical density, viscosity, particle size, and particle morphology. This range makes the technique highly suitable for monitoring bacterial cultivation processes, as was confirmed by initial pilot studies (11).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here